Vaccine Development for Schistosomiasis

Abstract

Background: Schistosomiasis could be prevented with vaccines. Vaccine developments are underway. These vaccines have reached clinical trials in humans or animals. \n \nObjectives: In this study, the author describes the progress in a study of schistosomiasis that focused on vaccine developments. \n \nMethodology: The author searched the PMC Database and PubMed Database on prevention of schistosomiasis. All were at National Center for Biotechnology Information (NCBI). The author also searched Google and Science Direct for schistosomiasis articles. Articles were unrestricted open access, articles needed permissions from Elsevier, and in English. \n \nResults: There are several vaccine candidates. These include such as Bilhvax (Sh28GST), Bilhvax is for Schistosoma haematobium schistotomisis. The Sh28GST vaccine has finished phase III clinical trial. Vaccine candidates for S. japonicum such as recombinant Sj26GST, Sj28GST and SjTP1Hsp 70 have been tried in such as buffalo, cattle, mice, and sheep. Vaccine candidates for S. mansoni are such as rSm14 + GLA-SE and rSm-p80 + GLA-SE. The rSm14 + GLE-SE is in human clinical trial phase 2 and rSm-p80 + GLE-SE is is in human clinical trial phase 3. Computational software can help in developing new vaccine candidates such as multi-epitope peptide-based vaccine for protecting people from schistosomiasis. \n \nConclusion: Vaccine candidates could include such as Sh28GST, Sj26GSST and Sm14 have been in clinical trials. Computational algorithms can help for creating multi-epitope peptide-based vaccines for schistosomiasis.